GlassScriptPhysician profile
Daljit Kaur Bagha
NPI 1225188162
$1,611.39
in general payments reported to CMS, 2019-2025
24 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.23 · 2020: $72.84 · 2021: $118 · 2022: $238 · 2023: $399 · 2024: $451 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $551.01 | 2022-2025 | Qelbree, Qelbree |
| Lilly USA, LLC | $195.86 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Ironshore Pharmaceuticals INC. | $131.80 | 2022-2024 | Jornay Pm |
| Novo Nordisk INC | $112.42 | 2020-2023 | Wegovy |
| Merck Sharp & Dohme LLC | $78.81 | 2022-2023 | Rotateq, Vaxelis, Gardasil 9 |
| Exact Sciences Corporation | $70.34 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.05 | 2019-2022 | |
| Neos Therapeutics, LP | $45.81 | 2022-2024 | Adzenys Xr-Odt |
| Astrazeneca Pharmaceuticals LP | $41.90 | 2020-2024 | Airsupra |
| Sanofi-Aventis U.S. LLC | $39.09 | 2023 | |
| Adlon Therapeutics L.P. | $34.68 | 2020-2021 | |
| Sobi, INC | $31.97 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $31.18 | 2019 | |
| Glaxosmithkline, LLC. | $21.28 | 2024 | Bexsero, Rotarix, Pediarix |
| Abbott Laboratories | $20.13 | 2023 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.78 | 2025 | |
| Ge Healthcare | $19.23 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.16 | 2022 | |
| Pfizer INC. | $18.11 | 2022 | |
| Shield Therapeutics INC | $17.57 | 2022 | |
| Cranial Technologies, INC | $14.66 | 2024 | Doc Band |
| Alk-Abello, INC | $14.28 | 2023 | Odactra, Grastek |
| Corium, LLC | $13.18 | 2023 | Azstarys |
| Indivior INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daljit Bagha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.